CABA

Cabaletta Bio Inc

Add to Watchlist

Advanced Chart

1.360

-0.09(-6.207%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.450

Open

1.450

VWAP

1.38

Vol

1.23M

Mkt Cap

124.39M

Low

1.350

Amount

1.70M

EV/EBITDA(TTM)

Total Shares

48.28M

-49.96M

EV/OCF(TTM)

P/S(TTM)

Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). Resecabtagene autoleucel, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.

9 Analyst Rating

1024.26% Upside

Wall Street analysts forecast CABA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CABA is 15.29 USD with a low forecast of 3.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

2 Hold

0 Sell

Strong Buy

1024.26% Upside

Current: 1.360

Low

3.00

Averages

15.29

High

25.00

1024.26% Upside

Current: 1.360

Low

3.00

Averages

15.29

High

25.00

Wells Fargo

Derek Archila

Equal Weight

downgrade

$3 -> $2

2025-08-08

New

Reason

Wells Fargo

Derek Archila

Price Target

$3 -> $2

2025-08-08

New

downgrade

Equal Weight

Reason

Wells Fargo analyst Derek Archila lowered the firm's price target on Cabaletta Bio to $2 from $3 and keeps an Equal Weight rating on the shares. The firm thinks the company's recent financing gives it time to gain more regulatory clarity for rese-cel in MG, SSc and SLE, but still falls short of its first BLA submission expected in 2027. Sentiment remains challenging and Wells expects shares to be range bound.

H.C. Wainwright

Buy

downgrade

$25 -> $16

2025-08-08

New

Reason

H.C. Wainwright

Price Target

$25 -> $16

2025-08-08

New

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Cabaletta Bio to $16 from $25 and keeps a Buy rating on the shares. The firm says accelerating enrollment lets rese-cel move towards registrational cohorts.

H.C. Wainwright

Douglas Tsao

Buy

maintain

$25

2025-06-11

Reason

H.C. Wainwright

Douglas Tsao

Price Target

$25

2025-06-11

maintain

Buy

Reason

H.C. Wainwright analyst Douglas Tsao reiterates a Buy rating and $25 price target on shares of Cabaletta, telling investors in a research note that "promising" initial efficacy and safety data from myositis, lupus and scleroderma cohorts solidify Cabaletta's position as a leader in developing cell therapy for autoimmune disease. Cabaletta reported "compelling" new data from 18 patients who were dosed with rese-cel across the REST-Myositis, -SLE and SSc studies at EULAR 2025, with seven out of eight patients from -Myositis achieving a clinical response off all immunomodulators, while off or actively tapering steroids and seven out of seven patients from -SLE achieved a clinical response off all immunomodulators and glucocorticoids, the firm says.

Citi

Buy

downgrade

$17 -> $13

2025-05-16

Reason

Citi

Price Target

$17 -> $13

2025-05-16

downgrade

Buy

Reason

Citi lowered the firm's price target on Cabaletta Bio to $13 from $17 and keeps a Buy rating on the shares post the Q1 report. The company has received FDA alignment on a registrational trial design for rese-cel in myositis and now anticipates application submission for full approval in 2027, the analyst tells investors in a research note. With regulatory alignment in hand, Citi thinks Cabaletta is leading in the myositis CAR-T space and could be first to launch.

Guggenheim

Buy

maintain

$23 -> $25

2025-05-15

Reason

Guggenheim

Price Target

$23 -> $25

2025-05-15

maintain

Buy

Reason

Guggenheim raised the firm's price target on Cabaletta Bio to $25 from $23 and keeps a Buy rating on the shares. After having touched base with management following the company's Q1 report, the firm argues that the ability of Cabaletta to align with FDA on "an efficient trial design significantly smaller and potentially faster than competitors" and with the potential for a broad label reinforces the firm's conviction in the company's strategic direction.

HC Wainwright & Co.

Douglas Tsao

Strong Buy

Reiterates

$25

2025-04-01

Reason

HC Wainwright & Co.

Douglas Tsao

Price Target

$25

2025-04-01

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Cabaletta Bio Inc (CABA.O) is -0.73, compared to its 5-year average forward P/E of -4.35. For a more detailed relative valuation and DCF analysis to assess Cabaletta Bio Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.35

Current PE

-0.73

Overvalued PE

-1.20

Undervalued PE

-7.49

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.97

Current EV/EBITDA

0.22

Overvalued EV/EBITDA

0.55

Undervalued EV/EBITDA

-4.50

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.85

Current PS

0.00

Overvalued PS

4.32

Undervalued PS

-2.62